The Medicare GLP-1 Bridge is now available to eligible Medicare beneficiaries, providing access to certain GLP-1 medications for weight management at a $50 monthly copayment. The federal program began July 1, 2026, and its current operating period runs through December 31, 2027.
The program was created by the Centers for Medicare & Medicaid Services (CMS) as a short-term demonstration. It is designed for qualifying Medicare Part D beneficiaries who need an eligible GLP-1 medication to reduce excess body weight or maintain weight reduction but do not qualify to receive that medication through their existing Medicare drug coverage.
The program has several eligibility rules. It also has specific requirements involving Medicare coverage, previous GLP-1 use, age, BMI and certain health conditions.
Understanding those rules is important because having Medicare alone does not automatically qualify someone for the $50 monthly benefit.
What the Medicare GLP-1 Bridge Does
The federal government launched the program as a temporary Medicare demonstration focused on access to certain GLP-1 medications for weight management.
Unlike a standard Medicare Part D benefit, the program operates outside the normal Part D coverage and payment structure. That difference affects how beneficiaries pay for the medicine and how their costs are counted.
Eligible beneficiaries pay $50 for a one-month supply of a covered medication.
The $50 amount does not change according to the beneficiary’s income. It also does not depend on which phase of the regular Part D benefit the person has reached.
That means the program does not use the normal Part D deductible or cost-sharing structure for the covered GLP-1 supplied through the demonstration.
The program is available nationwide, including U.S. states and territories, when beneficiaries meet the applicable requirements.
When the Program Began and How Long It Will Last
CMS started the program on July 1, 2026.
The current program period extends through December 31, 2027. CMS extended the demonstration after delaying the Medicare Part D portion of the BALANCE Model for 2027.
The extension gives CMS additional time to collect information about GLP-1 use among Medicare beneficiaries.
The data collected during the Bridge can help CMS and Medicare Part D plans evaluate future approaches to GLP-1 coverage.
For beneficiaries, the important point is that the current program has a defined end date.
The Bridge is not a permanent Medicare benefit. Its current authorization runs through the end of 2027.
Which GLP-1 Medications Are Available?
The program currently covers specific products when they are prescribed for the eligible weight-management purpose.
The covered products are:
| Medication | Covered formulation |
|---|---|
| Foundayo | All formulations currently listed by CMS |
| Wegovy | Injection and tablet formulations |
| Zepbound | KwikPen only |
The distinction involving Zepbound is particularly important.
The Bridge covers Zepbound KwikPen. Single-dose Zepbound pens and Zepbound vials are not included in the demonstration.
CMS can update the list of covered products and their National Drug Codes during the program.
The Bridge therefore should not be treated as blanket coverage for every GLP-1 medication available in the United States.
A beneficiary’s specific prescription must match the program’s eligible products and formulation requirements.
Why the Prescription’s Purpose Matters
The program focuses on weight management.
A beneficiary cannot simply use the Bridge because a particular GLP-1 medication is available through the program. The prescription must meet the program’s requirements.
CMS designed the demonstration for people seeking an eligible GLP-1 medication to reduce excess body weight or maintain weight reduction.
Some other medical uses fall under regular Medicare Part D coverage rules instead.
This distinction is central to determining eligibility.
For example, beneficiaries with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or certain forms of metabolic dysfunction-associated steatohepatitis may have access to GLP-1 treatment through their existing Part D coverage.
Those beneficiaries are not eligible to use the Bridge for those conditions simply because they meet the BMI requirements.
Who Can Qualify for the Program?
The program has four broad eligibility requirements.
First, the person must have Medicare Part D drug coverage through an eligible Medicare prescription drug arrangement.
Second, the beneficiary must not already be eligible to receive the GLP-1 through Medicare drug coverage.
Third, the person cannot have certain diagnoses that make the medication eligible for Part D coverage under the applicable rules.
Fourth, the beneficiary must satisfy the program’s age and BMI-related clinical criteria.
The rules are specific, so beneficiaries should review their individual circumstances with their healthcare provider.
Medicare Part D Enrollment Is Required
The Bridge is intended for people who have Medicare Part D drug coverage.
That can include a standalone Medicare Prescription Drug Plan or a Medicare health plan that includes prescription drug coverage.
However, certain Medicare plan types do not qualify.
CMS specifically identifies private fee-for-service plans, cost contract plans and PACE organizations among plan types that can make a beneficiary ineligible when they are the person’s only Medicare coverage.
Someone who is uncertain about their plan type can contact Medicare for help.
The program does not simply apply to everyone enrolled in Medicare Part A or Part B.
Part D coverage is a key requirement.
Previous GLP-1 Use Can Affect Eligibility
Another important rule concerns previous GLP-1 use through Medicare Part D.
If a beneficiary has received a GLP-1 medication paid for by their Medicare drug plan, they generally must continue obtaining that medication through the Part D plan rather than switching to the Bridge.
CMS reviews Medicare utilization data to determine whether a beneficiary previously received a GLP-1 through Part D.
The medications considered in this review include products containing semaglutide, tirzepatide, orforglipron, dulaglutide and liraglutide.
The rule can affect people who already had GLP-1 prescriptions before seeking access through the Bridge.
CMS has also stated that its 2026 review looks at GLP-1 utilization during calendar year 2026.
For 2027, CMS has not yet established the applicable lookback period in the guidance currently available.
Age and BMI Requirements
Beneficiaries must be at least 18 years old.
They must also meet at least one of the program’s clinical pathways.
The first pathway applies to people with a BMI of 35 or higher.
The second applies to people with a BMI of 30 or higher who also have certain qualifying health conditions.
Those conditions include certain types of heart failure, difficult-to-control high blood pressure and chronic kidney disease at stage 3a or higher.
A third pathway applies to people with a BMI of 27 or higher who have a qualifying condition or medical history.
Examples include prediabetes, a previous heart attack, a previous stroke or blocked arteries in the legs or arms.
The BMI used for the eligibility determination is tied to the time GLP-1 treatment began.
That detail can matter for someone whose BMI has changed since starting treatment.
BMI Does Not Have to Stay at the Same Level
CMS allows the clinical criteria to be evaluated based on the beneficiary’s status when GLP-1 treatment was initiated.
For example, someone could have started treatment when their BMI was at least 35 and later have a lower BMI.
A lower current BMI does not automatically eliminate eligibility if the original treatment initiation met the applicable criterion.
The prescribing provider must document or attest to the relevant information when completing the required authorization process.
This approach recognizes that a beneficiary’s weight can change during treatment.
It also prevents the eligibility calculation from depending solely on a person’s current BMI after treatment has already begun.
Certain Diagnoses Make Beneficiaries Ineligible for the Bridge
CMS excludes beneficiaries who have certain diagnoses from using the Bridge for those medical conditions.
The excluded conditions include:
- Type 2 diabetes
- Moderate-to-severe obstructive sleep apnea
- Certain noncirrhotic metabolic dysfunction-associated steatohepatitis, or MASH, cases with qualifying liver fibrosis
The reason is that these conditions can fall within Medicare Part D coverage rules for GLP-1 medications.
The Bridge is not intended to replace that existing coverage.
If a beneficiary has one of these conditions, the appropriate starting point is the person’s Medicare drug plan.
This rule remains important even if the beneficiary believes their Part D plan does not currently cover the medication.
How Much Does a Covered Medication Cost?
The beneficiary’s copayment under the Bridge is $50 per month.
The payment applies to an eligible one-month supply.
The $50 amount does not vary based on income.
It also does not become higher because a beneficiary has moved into another stage of the Part D benefit.
That makes the payment structure different from ordinary Part D prescription costs.
However, the $50 payment comes with an important limitation.
It does not count toward the beneficiary’s normal Part D deductible or yearly out-of-pocket calculation.
The Bridge operates separately from the Part D payment system.
The $50 Payment Does Not Count Toward Part D Out-of-Pocket Costs
Beneficiaries should not assume that the monthly Bridge payment will help them reach their regular Medicare Part D out-of-pocket threshold.
It does not.
The $50 copayment is outside the normal Part D benefit payment flow. It does not count toward true out-of-pocket costs, commonly known as TrOOP.
The same separation applies to the Medicare drug plan deductible.
The Bridge payment also does not receive the low-income subsidy treatment used within Part D.
In addition, covered Bridge medications are not eligible for the Medicare Prescription Payment Plan.
These differences can affect how beneficiaries plan their prescription expenses.
How Beneficiaries Apply for the Medication
There is not a separate public application that beneficiaries complete to enroll in the Bridge.
The process begins with a healthcare provider.
The general process involves several steps:
- Discuss GLP-1 treatment with a healthcare provider.
- Determine whether the beneficiary meets the clinical requirements.
- Have the provider send a prescription for an eligible product.
- Provide Medicare identification information to the pharmacy.
- Complete the required authorization process.
- Receive confirmation of eligibility and coverage.
- Pick up the prescription and pay the $50 copayment.
The pharmacy may request the beneficiary’s Medicare ID number.
The provider then submits the necessary information for authorization.
The beneficiary also receives confirmation from Medicare when coverage is approved.
How Prior Authorization Works
Prior authorization is an important part of the Bridge.
The process allows CMS to verify that the beneficiary meets the program’s requirements before the medication is covered through the demonstration.
The provider supplies information about the patient’s treatment and eligibility.
CMS guidance states that approved prior authorization remains valid through December 31, 2027.
After the first prescription is approved, the beneficiary generally does not need a new authorization for each refill if they remain on the same covered medication.
A dose change does not automatically require a new authorization.
A switch from one covered GLP-1 product to another can require a new authorization.
This distinction allows treatment to continue while maintaining the program’s eligibility controls.
What Happens at the Pharmacy?
The Bridge uses a central processing system for claims.
CMS selected Humana to serve as the central processor for the program.
The processor handles prior authorization, claims adjudication and payments to pharmacies.
The Bridge acts as the primary payer for eligible prescriptions covered under the demonstration.
Pharmacies collect the $50 beneficiary copayment and receive reimbursement through the central processing system.
Claims are processed electronically.
Paper claims and direct reimbursement to beneficiaries are not accepted through the central processor.
These procedures help separate Bridge claims from standard Medicare Part D claims.
Can Coupons Reduce the $50 Copayment?
No.
The $50 Bridge copayment cannot be reduced through manufacturer coupons or other discount programs.
The Bridge is the primary payer for eligible prescriptions and does not coordinate benefits with other payers.
The beneficiary remains responsible for the $50 copayment.
This means beneficiaries should not expect commercial coupon programs to reduce the amount they owe when the prescription is processed through the Bridge.
The rule applies regardless of the source of the discount assistance.
What Happens When a Beneficiary Changes Medications?
Changing medications can affect the authorization process.
If a beneficiary remains on the same covered GLP-1, refills generally do not require a new authorization after the first approval.
Dose changes can also occur without requiring a new authorization as long as the beneficiary stays on the same covered product.
However, switching to another eligible GLP-1 can trigger a new authorization requirement.
The pharmacy’s claim processing system checks eligibility when prescriptions are submitted.
A claim can be rejected if the beneficiary no longer meets the program requirements.
The Program Is Separate From Regular Medicare Drug Coverage
The Bridge does not replace Medicare Part D.
Instead, it creates a separate pathway for qualifying beneficiaries who meet the demonstration’s requirements.
That distinction matters when comparing the Bridge with regular prescription coverage.
Under ordinary Part D coverage, the beneficiary’s plan determines whether a medication is covered based on its formulary and applicable coverage rules.
Under the Bridge, CMS has established a specific list of eligible GLP-1 products and clinical criteria.
The program also uses the fixed $50 monthly copayment.
Beneficiaries should therefore determine whether their medication is already covered through Part D before seeking Bridge coverage.
What the 2027 Extension Means
CMS has confirmed that the Bridge will continue through December 31, 2027.
The agency extended the program after delaying the Medicare Part D portion of the BALANCE Model for calendar year 2027.
The continued Bridge gives CMS additional time to collect information about GLP-1 utilization.
That information can be shared with Part D plan sponsors as CMS evaluates potential future implementation of BALANCE in Part D.
For beneficiaries, the immediate result is continued access to the Bridge under its current rules through the end of 2027.
The extension does not turn the Bridge into a permanent Medicare benefit.
Current Program Details at a Glance
| Program detail | Current information |
|---|---|
| Start date | July 1, 2026 |
| Current end date | December 31, 2027 |
| Program type | CMS short-term demonstration |
| Required coverage | Medicare Part D |
| Beneficiary copayment | $50 per month |
| Part D deductible | Does not apply |
| Part D out-of-pocket calculation | Bridge payment does not count |
| Minimum age | 18 |
| Main purpose | Weight management |
| Current eligible products | Foundayo, Wegovy, Zepbound KwikPen |
| Zepbound limitation | KwikPen only |
| Geographic availability | All states and territories |
| Prior authorization | Required |
| Authorization period | Through December 31, 2027 |
| Central processor | Humana |
What Medicare Beneficiaries Should Check Before Seeking Coverage
People considering the program should review several details before assuming they qualify.
First, verify that the Medicare coverage includes Part D.
Next, determine whether the prescribed medication is one of the products included in the Bridge.
The beneficiary should also discuss the prescription’s purpose with the healthcare provider.
BMI history can matter as well. The relevant measurement may be the BMI at the time GLP-1 treatment began.
Previous GLP-1 use through Medicare Part D is another important eligibility issue.
Finally, beneficiaries with type 2 diabetes, qualifying sleep apnea or certain MASH diagnoses should first contact their Medicare drug plan because those conditions can fall under existing Part D coverage.
Frequently Asked Questions
What is the Medicare GLP-1 Bridge?
It is a CMS demonstration that provides certain eligible Medicare Part D beneficiaries with access to selected GLP-1 medications for weight management at a $50 monthly copayment.
How much does the program cost?
Eligible beneficiaries pay $50 for a one-month supply of a covered medication.
When did the program start?
The Bridge began July 1, 2026.
When does the program end?
The current program period ends December 31, 2027.
Which medications are included?
The current covered products are Foundayo, Wegovy and Zepbound KwikPen when prescribed for the qualifying weight-management purpose.
Are Zepbound vials covered?
No. The Bridge covers the KwikPen formulation. Single-dose Zepbound pens and vials are not included.
Does Medicare Part D cover the $50 payment?
The Bridge operates outside the normal Part D benefit. The $50 copayment does not count toward the Part D deductible or TrOOP.
Can someone with Medicare Advantage qualify?
Certain Medicare Advantage plans that include Part D drug coverage can qualify, provided the beneficiary meets the other program requirements.
Does a beneficiary with type 2 diabetes qualify through the Bridge?
No. The Bridge is intended for weight-management use. CMS directs beneficiaries with type 2 diabetes toward their Medicare drug plan for applicable GLP-1 coverage.
Does current BMI determine eligibility?
The clinical criteria are based on the beneficiary’s circumstances when GLP-1 treatment was initiated. A provider must attest to the applicable information.
Can a person change the dose without another authorization?
Generally, yes, when the beneficiary remains on the same covered GLP-1 medication.
Does switching GLP-1 medications require new authorization?
A switch between covered GLP-1 products can require a new prior authorization.
Can coupons reduce the $50 copayment?
No. Coupons and discount programs cannot be applied to Bridge claims.
Is the program available nationwide?
Yes. CMS says the demonstration is available across all states and U.S. territories for eligible beneficiaries.
What to Know About the Program Now
The Medicare GLP-1 Bridge provides a defined pathway for eligible Part D beneficiaries seeking certain GLP-1 medications for weight management.
Its most recognizable feature is the $50 monthly copayment, but the eligibility rules are equally important. Medicare Part D enrollment, previous GLP-1 coverage, age, BMI, medical conditions and prescription purpose can all affect access.
The current program includes Foundayo, Wegovy and Zepbound KwikPen, with specific formulation restrictions. It operates outside standard Part D coverage and does not make the $50 payment count toward normal Part D out-of-pocket costs.
CMS currently plans to keep the demonstration in place through December 31, 2027. Beneficiaries who believe they qualify should discuss the requirements with their healthcare provider and confirm their Medicare coverage before filling a prescription through the program.
Have questions about the Medicare GLP-1 Bridge or how the current rules may affect beneficiaries? Share your thoughts below and stay informed about the latest confirmed Medicare updates.